Economic Evaluation in Stroke Research

Evers, Silvia M. A. A.; Goossens, Mariëlle E. J. B.; Ament, André; Maarse, J.A.M.

doi:10.1159/000047617

Cited by 15 publications

(13 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results support the findings of existing reviews 4,[33][34][35][36][37][38][39] in that cerebrovascular diseases pose a significant economic burden. However, previous reviews have tended to focus on specific types of costing studies such as those used as part of an economic evaluation.…”

Section: Luengo-fernandez Et Al Cerebrovascular Disease Costs E21supporting

confidence: 91%

Costs of Stroke Using Patient-Level Data

Luengo-Fernández

Gray

Rothwell

2009

Stroke

122

View full text Add to dashboard Cite

Background and Purpose-With decision-analytic models becoming more popular to assess the cost-effectiveness of health care interventions, the need for robust estimates on the costs of cerebrovascular disease is paramount. This study reports the results from a literature review of the costs of cerebrovascular diseases, and assesses the quality of the published evidence against a set of defined criteria. Methods-A broad literature search was conducted. Those studies reporting mean/median costs of cerebrovascular diseases derived from patient-level data in a developed country setting were included. Data were abstracted using standardized reporting forms and assessed against 4 predefined criteria: use of adequate methodologies, use of a population-based study, inclusion of premorbid resource use, and reporting of costs by different patient subgroups. Results-A total of 120 cost studies were identified. The cost estimates of stroke were compared by taking into account the effects of inflation and price differentials between countries. Average costs of stroke ranged from $468 to $146 149. Differences in costs were also found within country, with estimates in the USA varying 20-fold. Although the costing methodologies used were generally appropriate, only 5 studies were based on population-based studies, which are the gold standard study design when comparing incidence, outcome, and costs. Conclusions-This review showed large variations in the costs of stroke, mainly attributable to differences in the populations studied, methods, and cost categories included. The wide range of cost estimates could lead to selection bias in secondary health economic analyses, with authors including those costs that are more likely to produce the desired results. (Stroke. 2009;40:e18-e23.)

show abstract

Section: Luengo-fernandez Et Al Cerebrovascular Disease Costs E21supporting

confidence: 91%

Costs of Stroke Using Patient-Level Data

Luengo-Fernández

Gray

Rothwell

2009

Stroke

122

View full text Add to dashboard Cite

show abstract

“…excluding social care and indirect costs) in Europe and the USA. 15 The cost of stroke in the UK is high at £2300 million per year, and accounts for about 6% of total NHS and Social Services expenditure; this is nearly twice the amount spent on coronary heart disease (CHD). 2,16 Despite this high disease burden on society and high cost, little is known about the key aspects of managing stroke and how they affect the outcome and the cost.…”

Section: The Cost Of Strokementioning

confidence: 99%

“…One study (15 neuroimaging twice within the first 24 hours, the first scan negative and the second scan positive for haemorrhage. 117 They suggested that early haemorrhagic transformation may present as primary intracerebral haemorrhage if patients are not scanned very early.…”

Section: Studies Of Ct and Haemorrhagic Transformationmentioning

confidence: 99%

“…A systematic review of stroke and stroke survivors indicated that 4.3% of survivors have any recurrent stroke (CI 3.5% to 5.4%), 2.4% have a haemorrhagic stroke (CI 1.9% to 2.7%) and these gave 8.8% deaths per year (CI 5.2% to 11.0%) (assuming aspirin was not given). 122 If aspirin was given this would result in a 3.7% (2.7% to 3.8%) increase in haemorrhagic stroke and a 12.3% (CI 7.3% to 15 …”

Section: Ct Scanning Strategies Diagnosis Treatment Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

What is the best imaging strategy for acute stroke?

Wardlaw

Keir

Seymour

et al. 2005

Int J Technol Assess Health Care

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAWhat is the best imaging strategy for acute stroke? NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care) rather than settings of care. Therefore the panel structure was replaced in 2000 by three new panels: Pharmaceuticals; Therapeutic Procedures (including devices and operations); and Diagnostic Technologies and Screening.The HTA Programme will continue to commission both primary and secondary research. The HTA Commissioning Board, supported by the National Coordinat...

show abstract

“…R educing the cost of health care has become increasingly important in the advent of rising costs, 1 and the treatment of stroke is no exception. 2 The high morbidity associated with stroke contributes to the economic burden of this condition worldwide, [3][4][5] with hospital costs accounting for 71% of the total stroke care costs.…”

mentioning

confidence: 99%

Costs and Caregiver Consequences of Early Supported Discharge for Stroke Patients

Teng

Mayo

Latimer

et al. 2003

Stroke

103

104

View full text Add to dashboard Cite

Background and Purpose-Early supported discharge (ESD) for stroke has been shown to yield outcomes similar to or better than those of conventional care, but there is less information on the impact on costs and on the caregiver. The purpose of this study is to estimate the costs associated with an ESD program compared with those of usual care. Methods-We conducted a randomized controlled trial of stroke patients who required rehabilitation services and who had a caregiver at home. Results-Acute-care costs incurred before randomization when patients were medically ready for discharge averaged $3251 per person. The costs for the balance of the acute-care stay, from randomization to discharge, were $1383 for the home group and $2220 for the usual care group. The average cost of providing the 4-week home intervention service was $943 per person. The total cost generated by persons assigned to the home group averaged $7784 per person, significantly lower than the $11 065 per person for those assigned to usual care. A large proportion of the cost differential between the 2 groups arose from readmissions, for which the usual care group generated costs more than quadruple those of the home intervention group. Conclusions-Providing

show abstract

Economic Evaluation in Stroke Research

Cited by 15 publications

References 41 publications

Costs of Stroke Using Patient-Level Data

Costs of Stroke Using Patient-Level Data

What is the best imaging strategy for acute stroke?

Costs and Caregiver Consequences of Early Supported Discharge for Stroke Patients

Contact Info

Product

Resources

About